Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.
Quality of life (QL) is an important consideration when comparing adjuvant therapies for early breast cancer, especially if they differ substantially in toxicity. We evaluated QL and Q-TWiST among patients randomised to adjuvant dose-intensive epirubicin and cyclophosphamide administered with filgrastim and progenitor cell support (DI-EC) or standard-dose anthracycline-based chemotherapy (SD-CT). We estimated the duration of chemotherapy toxicity (TOX), time without disease symptoms and toxicity (TWiST), and time following relapse (REL). Patients scored QL indicators. Mean durations for the three transition times were weighted with patient reported utilities to obtain mean Q-TWiST. Patients receiving DI-EC reported worse QL during TOX, especially treatment burden (month 3: P<0.01), but a faster recovery 3 months following chemotherapy than patients receiving SD-CT, for example, less coping effort (P<0.01). Average Q-TWiST was 1.8 months longer for patients receiving DI-EC (95% CI, -2.5 to 6.1). Q-TWiST favoured DI-EC for most values of utilities attached to TOX and REL. Despite greater initial toxicity, quality-adjusted survival was similar or better with dose-intensive treatment as compared to standard treatment. Thus, QL considerations should not be prohibitive if future intensive therapies show superior efficacy.
IBCSG Coordinating Center, Effingerstrasse 40, Bern 3008, Switzerland. juerg.bernhard@ibcsg.org
J
J
Bernhard
D
D
Zahrieh
J J
JJ
Zhang
G
G
Martinelli
R
R
Basser
C
C
Hürny
J F
JF
Forbes
S
S
Aebi
W
W
Yeo
B
B
Thürlimann
M D
MD
Green
M
M
Colleoni
R D
RD
Gelber
M
M
Castiglione-Gertsch
K N
KN
Price
A
A
Goldhirsch
A S
AS
Coates
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D012307:Risk Factors; D015996:Survival Rate
D015251:Epirubicin; D004317:Doxorubicin; D003520:Cyclophosphamide